{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:39:57Z","timestamp":1792550397461,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04504-x","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:34:59Z","timestamp":1784907299000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma"],"prefix":"10.1007","volume":"75","author":[{"given":"Dong Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Kyung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeong Cheon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungirl","family":"Seok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Jae","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Keun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon-Hyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"1","key":"4504_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR (2020) Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6(1):92","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"4504_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra1715715","volume":"382","author":"LQ Chow","year":"2020","unstructured":"Chow LQ (2020) Head and neck cancer. N Engl J Med 382(1):60\u201372","journal-title":"N Engl J Med"},{"issue":"1","key":"4504_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01504-0","volume":"15","author":"DH Kim","year":"2024","unstructured":"Kim DH, Kang M, Park G et al (2024) Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors. Discov Oncol 15(1):686","journal-title":"Discov Oncol"},{"key":"4504_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hed.25930","volume":"41","author":"HF Kao","year":"2019","unstructured":"Kao HF, Lou PJ (2019) Immune checkpoint inhibitors for head and neck squamous cell carcinoma: current landscape and future directions. Head Neck 41:4\u201318","journal-title":"Head Neck"},{"issue":"10318","key":"4504_CR5","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/S0140-6736(21)01550-6","volume":"398","author":"MD Mody","year":"2021","unstructured":"Mody MD, Rocco JW, Yom SS, Haddad RI, Saba NF (2021) Head and neck cancer. The Lancet 398(10318):2289\u20132299","journal-title":"The Lancet"},{"issue":"9","key":"4504_CR6","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.21873\/anticanres.12862","volume":"38","author":"S Merz","year":"2018","unstructured":"Merz S, Timmesfeld N, Stuck BA, Wiegand S (2018) Impact of lymph node yield on outcome of patients with head and neck cancer and pN0 neck. Anticancer Res 38(9):5347\u20135350","journal-title":"Anticancer Res"},{"issue":"1","key":"4504_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.trecan.2023.09.006","volume":"10","author":"I Delclaux","year":"2024","unstructured":"Delclaux I, Ventre KS, Jones D, Lund AW (2024) The tumor-draining lymph node as a reservoir for systemic immune surveillance. Trends in cancer 10(1):28\u201337","journal-title":"Trends in cancer"},{"issue":"1","key":"4504_CR8","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1038\/s41467-022-31941-w","volume":"13","author":"R Saddawi-Konefka","year":"2022","unstructured":"Saddawi-Konefka R, O\u2019farrell A, Faraji F et al (2022) Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC. Nat Commun 13(1):4298","journal-title":"Nat Commun"},{"issue":"9","key":"4504_CR9","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8(9):1069\u20131086","journal-title":"Cancer Discov"},{"issue":"18","key":"4504_CR10","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.3390\/cells13181557","volume":"13","author":"DH Kim","year":"2024","unstructured":"Kim DH, Ahn JS, Kang M et al (2024) Comparison of tumor microenvironments between primary tumors and lymph node metastases in head and neck squamous cell carcinoma and their predictive role in immune checkpoint inhibitor treatment. Cells 13(18):1557","journal-title":"Cells"},{"issue":"6","key":"4504_CR11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.oooo.2024.07.014","volume":"138","author":"DH Kim","year":"2024","unstructured":"Kim DH, Jang SY, Keam B (2024) Predictive value of early dynamic changes of NLR and PLR for the efficacy of immune checkpoint inhibitor in head and neck squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 138(6):763\u2013771","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"2","key":"4504_CR12","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.21873\/anticanres.18010","volume":"46","author":"Y-I Iwasa","year":"2026","unstructured":"Iwasa Y-I, Hori K, Yokota Y et al (2026) Neck dissection and immune checkpoint inhibitor efficacy in head and neck cancer: a retrospective study. Anticancer Res 46(2):1079\u20131087","journal-title":"Anticancer Res"},{"issue":"2","key":"4504_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020191","volume":"8","author":"A Botticelli","year":"2020","unstructured":"Botticelli A, Mezi S, Pomati G et al (2020) The impact of locoregional treatment on response to nivolumab in advanced platinum refractory head and neck cancer: the need trial. Vaccines (Basel) 8(2):191","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"4504_CR14","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s10147-021-01900-4","volume":"26","author":"S Kariya","year":"2021","unstructured":"Kariya S, Shimizu Y, Hanai N et al (2021) Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting. Int J Clin Oncol 26(6):1049\u20131056","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"4504_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/lio2.70120","volume":"10","author":"AM Patel","year":"2025","unstructured":"Patel AM, Haleem A, Cowan PT, Roden DF (2025) Neck dissection and survival among head and neck cancer patients undergoing adjuvant immunotherapy. Laryngoscope Investig Otolaryngol 10(2):e70120","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"6","key":"4504_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1056\/NEJMoa1506007","volume":"373","author":"AK D\u2019Cruz","year":"2015","unstructured":"D\u2019Cruz AK, Vaish R, Kapre N et al (2015) Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med 373(6):521\u2013529","journal-title":"N Engl J Med"},{"issue":"3","key":"4504_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/0194599815622409","volume":"154","author":"A Lemieux","year":"2016","unstructured":"Lemieux A, Kedarisetty S, Raju S, Orosco R, Coffey C (2016) Lymph node yield as a predictor of survival in pathologically node negative oral cavity carcinoma. Otolaryngol Head Neck Surg 154(3):465\u2013472","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"4504_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s44276-024-00095-1","volume":"2","author":"K Payne","year":"2024","unstructured":"Payne K, Nenclares P, Schilling C (2024) The impact of elective cervical lymph node treatment on the tumour immune response in head and neck squamous cell carcinoma: time for a change in treatment strategy? BJC reports 2(1):68","journal-title":"BJC reports"},{"issue":"12","key":"4504_CR19","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE et al (2022) Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer. J Clin Oncol 40(12):1301\u20131311","journal-title":"J Clin Oncol"},{"issue":"18","key":"4504_CR20","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1001\/jama.2025.1483","volume":"333","author":"R Haddad","year":"2025","unstructured":"Haddad R, Fayette J, Teixeira M et al (2025) Atezolizumab in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomized clinical trial. JAMA 333(18):1599\u20131607","journal-title":"JAMA"},{"issue":"5","key":"4504_CR21","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","volume":"25","author":"J-P Machiels","year":"2024","unstructured":"Machiels J-P, Tao Y, Licitra L et al (2024) Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol 25(5):572\u2013587","journal-title":"Lancet Oncol"},{"issue":"4","key":"4504_CR22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","volume":"22","author":"NY Lee","year":"2021","unstructured":"Lee NY, Ferris RL, Psyrri A et al (2021) Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 22(4):450\u2013462","journal-title":"Lancet Oncol"},{"issue":"12","key":"4504_CR23","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/S1470-2045(24)00507-2","volume":"25","author":"LK Mell","year":"2024","unstructured":"Mell LK, Torres-Saavedra PA, Wong SJ et al (2024) Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2\/3 trial. Lancet Oncol 25(12):1576\u20131588","journal-title":"Lancet Oncol"},{"issue":"10","key":"4504_CR24","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jamaoto.2021.2191","volume":"147","author":"R Masarwy","year":"2021","unstructured":"Masarwy R, Kampel L, Horowitz G, Gutfeld O, Muhanna N (2021) Neoadjuvant PD-1\/PD-L1 inhibitors for resectable head and neck cancer: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg 147(10):871\u2013878","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"1","key":"4504_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","volume":"393","author":"R Uppaluri","year":"2025","unstructured":"Uppaluri R, Haddad RI, Tao Y et al (2025) Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer. N Engl J Med 393(1):37\u201350","journal-title":"N Engl J Med"},{"key":"4504_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.106739","volume":"151","author":"DH Kim","year":"2024","unstructured":"Kim DH, Lim ST, Kim HR et al (2024) Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: post hoc analysis of TRIUMPH study. Oral Oncol 151:106739","journal-title":"Oral Oncol"},{"issue":"1","key":"4504_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/annonc\/mdy507","volume":"30","author":"M Oliva","year":"2019","unstructured":"Oliva M, Spreafico A, Taberna M et al (2019) Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. Ann Oncol 30(1):57\u201367","journal-title":"Ann Oncol"},{"issue":"10212","key":"4504_CR28","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet 394(10212):1915\u20131928","journal-title":"The Lancet"},{"key":"4504_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2025.11.018","author":"DH Kim","year":"2025","unstructured":"Kim DH, Koh J, Ahn JS et al (2025) PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. https:\/\/doi.org\/10.1016\/j.oooo.2025.11.018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"4504_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153605","volume":"226","author":"G Paolino","year":"2021","unstructured":"Paolino G, Pantanowitz L, Barresi V et al (2021) PD-L1 evaluation in head and neck squamous cell carcinoma: insights regarding specimens, heterogeneity and therapy. Pathol Res Pract 226:153605","journal-title":"Pathol Res Pract"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04504-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04504-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04504-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:16:58Z","timestamp":1792549018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04504-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["4504"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04504-x","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.K. received research funding from MSD, AstraZeneca, Bayer, and Ono Pharmaceutical Co., Ltd., and has served as an advisor for Handok, Yuhan, Trialinformatics, TiumBio, and BeOne outside of the current work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines. The study protocol was approved by the Institutional Review Board of each participating institution (SNUH IRB no. 2602-040-1716).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"251"}}